Related Experiment Video

Updated: May 15, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Novel pathway for somatostatin analogs in patients with acromegaly

Mônica R Gadelha1, Leandro Kasuki, Márta Korbonits

  • 1Division of Endocrinology, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Professor Rodolpho Paulo Rocco street 255, Rio de Janeiro, Brazil.

Trends in Endocrinology and Metabolism: TEM
|December 29, 2012
PubMed

Insights

This review explores the somatostatin analog (SSA) pathway involving aryl hydrocarbon receptor-interacting protein (AIP) and ZAC1. Understanding this pathway may improve acromegaly treatment, especially for patients resistant to current therapies.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Acromegaly, a chronic condition, often requires multiple treatments due to high morbidity and mortality.
  • Somatostatin analogs (SSAs) are primary medical treatments, but many patients, including those with aryl hydrocarbon receptor-interacting protein (AIP) gene mutations, show resistance.
  • The tumor suppressor gene ZAC1's role in SSA action and its regulation by AIP are emerging areas of research.

Purpose of the Study:

  • To review novel findings on the SSA-AIP-ZAC1 pathway.
  • To highlight the significance of this pathway in treating sporadic and familial somatotroph adenomas.
  • To discuss potential therapeutic implications for acromegaly management.

Main Methods:

  • Literature review of recent studies on SSA, AIP, and ZAC1.
  • Analysis of proposed molecular mechanisms and signaling pathways.
  • Discussion of clinical relevance for somatotroph adenomas.

Main Results:

  • Evidence suggests SSAs may regulate AIP, which in turn stimulates ZAC1.
  • A potential SSA-AIP-ZAC1-somatostatin signaling pathway is proposed.
  • This pathway may explain treatment resistance in some acromegaly patients.

Conclusions:

  • The SSA-AIP-ZAC1 pathway offers new insights into acromegaly pathogenesis.
  • Targeting this pathway could lead to improved therapeutic strategies for resistant somatotroph adenomas.
  • Further research is warranted to elucidate the full clinical impact.

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines12:06

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines

Published on: November 25, 2017

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Sympathetic Pathways: Collateral Ganglia and Adrenal Medulla01:27

Sympathetic Pathways: Collateral Ganglia and Adrenal Medulla

The sympathetic pathways of the collateral ganglia and adrenal medulla serve unique but interconnected roles in the sympathetic response.
Collateral Ganglia
Sympathetic preganglionic axons reach the collateral ganglia along the route of splanchnic nerves. These nerves bypass the sympathetic trunk and communicate with sympathetic postganglionic neurons housed in the prevertebral ganglia. These ganglia supply the organs of the abdominopelvic cavity.
The greater splanchnic nerve, formed by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...